HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer cells

Takayuki MacHino, Yasushi Okoshi, Yasuyuki Miyake, Yoshiki Akatsuka, Shigeru Chiba

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Risk of leukemia relapse after T cell-depleted hematopoietic stem cell transplantation is lower in the "HLA-C mismatched" recipient-donor combinations. This might be attributable to increased natural killing by allogeneic NK cells carrying a KIR that does not bind to HLA-C on target cells (HLA-C-uncoupled KIR). Considering a new strategy of allogeneic NK cell transfer with rituximab to treat B-cell lymphomas, however, it is unknown whether the HLA-C matching status also affects rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC). To address this issue, we investigated the levels of ADCC by purified NK cells carrying an HLA-C-uncoupled KIR, where the NK cell donors had either matched or mismatched HLA-C combination with target cells. Purified NK cells carrying an HLA-C-uncoupled KIR consistently showed enhanced ADCC against target cells when NK cell donors had an HLA-C-mismatch. When NK cell donors did not have an HLA-C mismatch, it was inconsistent whether HLA-C-uncoupled KIR caused ADCC enhancement. When the levels of ADCC by whole NK cells were compared, there were substantial differences among the donors regardless of the HLA-C matching status. Subjects with HLA-C mismatch may not have an advantage when cytoimmunotherapy using allogeneic NK cells is considered in combination with rituximab.

Original languageEnglish
Pages (from-to)831-846
Number of pages16
JournalImmunological Investigations
Volume41
Issue number8
DOIs
Publication statusPublished - 17-12-2012

Fingerprint

HLA-C Antigens
Natural Killer Cells
Antibodies
Rituximab
Hematopoietic Stem Cell Transplantation
B-Cell Lymphoma

All Science Journal Classification (ASJC) codes

  • Immunology

Cite this

MacHino, Takayuki ; Okoshi, Yasushi ; Miyake, Yasuyuki ; Akatsuka, Yoshiki ; Chiba, Shigeru. / HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer cells. In: Immunological Investigations. 2012 ; Vol. 41, No. 8. pp. 831-846.
@article{ba8951cb73594041891d7aa31092687a,
title = "HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer cells",
abstract = "Risk of leukemia relapse after T cell-depleted hematopoietic stem cell transplantation is lower in the {"}HLA-C mismatched{"} recipient-donor combinations. This might be attributable to increased natural killing by allogeneic NK cells carrying a KIR that does not bind to HLA-C on target cells (HLA-C-uncoupled KIR). Considering a new strategy of allogeneic NK cell transfer with rituximab to treat B-cell lymphomas, however, it is unknown whether the HLA-C matching status also affects rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC). To address this issue, we investigated the levels of ADCC by purified NK cells carrying an HLA-C-uncoupled KIR, where the NK cell donors had either matched or mismatched HLA-C combination with target cells. Purified NK cells carrying an HLA-C-uncoupled KIR consistently showed enhanced ADCC against target cells when NK cell donors had an HLA-C-mismatch. When NK cell donors did not have an HLA-C mismatch, it was inconsistent whether HLA-C-uncoupled KIR caused ADCC enhancement. When the levels of ADCC by whole NK cells were compared, there were substantial differences among the donors regardless of the HLA-C matching status. Subjects with HLA-C mismatch may not have an advantage when cytoimmunotherapy using allogeneic NK cells is considered in combination with rituximab.",
author = "Takayuki MacHino and Yasushi Okoshi and Yasuyuki Miyake and Yoshiki Akatsuka and Shigeru Chiba",
year = "2012",
month = "12",
day = "17",
doi = "10.3109/08820139.2012.691148",
language = "English",
volume = "41",
pages = "831--846",
journal = "Immunological Investigations",
issn = "0882-0139",
publisher = "Informa Healthcare",
number = "8",

}

HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer cells. / MacHino, Takayuki; Okoshi, Yasushi; Miyake, Yasuyuki; Akatsuka, Yoshiki; Chiba, Shigeru.

In: Immunological Investigations, Vol. 41, No. 8, 17.12.2012, p. 831-846.

Research output: Contribution to journalArticle

TY - JOUR

T1 - HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer cells

AU - MacHino, Takayuki

AU - Okoshi, Yasushi

AU - Miyake, Yasuyuki

AU - Akatsuka, Yoshiki

AU - Chiba, Shigeru

PY - 2012/12/17

Y1 - 2012/12/17

N2 - Risk of leukemia relapse after T cell-depleted hematopoietic stem cell transplantation is lower in the "HLA-C mismatched" recipient-donor combinations. This might be attributable to increased natural killing by allogeneic NK cells carrying a KIR that does not bind to HLA-C on target cells (HLA-C-uncoupled KIR). Considering a new strategy of allogeneic NK cell transfer with rituximab to treat B-cell lymphomas, however, it is unknown whether the HLA-C matching status also affects rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC). To address this issue, we investigated the levels of ADCC by purified NK cells carrying an HLA-C-uncoupled KIR, where the NK cell donors had either matched or mismatched HLA-C combination with target cells. Purified NK cells carrying an HLA-C-uncoupled KIR consistently showed enhanced ADCC against target cells when NK cell donors had an HLA-C-mismatch. When NK cell donors did not have an HLA-C mismatch, it was inconsistent whether HLA-C-uncoupled KIR caused ADCC enhancement. When the levels of ADCC by whole NK cells were compared, there were substantial differences among the donors regardless of the HLA-C matching status. Subjects with HLA-C mismatch may not have an advantage when cytoimmunotherapy using allogeneic NK cells is considered in combination with rituximab.

AB - Risk of leukemia relapse after T cell-depleted hematopoietic stem cell transplantation is lower in the "HLA-C mismatched" recipient-donor combinations. This might be attributable to increased natural killing by allogeneic NK cells carrying a KIR that does not bind to HLA-C on target cells (HLA-C-uncoupled KIR). Considering a new strategy of allogeneic NK cell transfer with rituximab to treat B-cell lymphomas, however, it is unknown whether the HLA-C matching status also affects rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC). To address this issue, we investigated the levels of ADCC by purified NK cells carrying an HLA-C-uncoupled KIR, where the NK cell donors had either matched or mismatched HLA-C combination with target cells. Purified NK cells carrying an HLA-C-uncoupled KIR consistently showed enhanced ADCC against target cells when NK cell donors had an HLA-C-mismatch. When NK cell donors did not have an HLA-C mismatch, it was inconsistent whether HLA-C-uncoupled KIR caused ADCC enhancement. When the levels of ADCC by whole NK cells were compared, there were substantial differences among the donors regardless of the HLA-C matching status. Subjects with HLA-C mismatch may not have an advantage when cytoimmunotherapy using allogeneic NK cells is considered in combination with rituximab.

UR - http://www.scopus.com/inward/record.url?scp=84870939008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870939008&partnerID=8YFLogxK

U2 - 10.3109/08820139.2012.691148

DO - 10.3109/08820139.2012.691148

M3 - Article

VL - 41

SP - 831

EP - 846

JO - Immunological Investigations

JF - Immunological Investigations

SN - 0882-0139

IS - 8

ER -